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XRCC4 plays a crucial role in the nonhomologous end joining
(NHEJ) pathway of DNA double-strand break repair acting as a
scaffold protein that recruits other NHEJ proteins to double-
strand breaks. Phosphorylation of XRCC4 by protein kinase
CK2 promotes a high affinity interaction with the forkhead-as-
sociated domain of the end-processing enzyme polynucleotide
kinase/phosphatase (PNKP). Here we reveal that unphosphory-
lated XRCC4 also interacts with PNKP through a lower affinity
interaction site within the catalytic domain and that this inter-
action stimulates the turnover of PNKP. Unexpectedly, CK2-
phosphorylated XRCC4 inhibited PNKP activity. Moreover, the
XRCC4DNA ligase IV complex also stimulated PNKP enzyme
turnover, and this effect was independent of the phosphoryla-
tion of XRCC4 at threonine 233. Our results reveal that CK2-
mediated phosphorylation of XRCC4 can have different effects
on PNKP activity, with implications for the roles of XRCC4 and
PNKP in NHEJ.
Efficient repair of DNA double-strand breaks (DSBs)3 is crit-
ical for the maintenance of genome stability. In mammalian
cells, nonhomologous end joining (NHEJ) is themajor pathway
that repairs these DSBs (1, 2). Although many of the individual
components involved in the NHEJ repair pathway are well
established, the dynamics of the repair pathway remains poorly
understood. One approach to achieving a better understanding
of the step-by-step choreography of each enzymatic process,
including the nature of the binding of repair proteins to their
DNA substrates and to each other, is to use a detailed quanti-
tative approach in which specific protein-protein and protein-
DNA interactions are not just identified qualitatively but are
accurately quantified, giving an estimation of their respective
affinities.
XRCC4 is regarded as a scaffold protein that recruits other
proteins to DSBs (1). Of note, XRCC4 interacts with and cata-
lytically stimulates the activity of DNA ligase IV (3, 4) to carry
out the final step in the NHEJ pathway, joining the DNA ends
(5). More recently, XRCC4 has been shown to interact with
polynucleotide kinase/phosphatase (PNKP) (6, 7), a bifunc-
tional enzyme that phosphorylates 5-OH termini and dephos-
phorylates 3-phosphate termini (8–11), thereby providing the
correct chemical end groups required forDNA ligation byDNA
ligase IV. Because XRCC4 is an efficient substrate for DNA-PK
in vitro (12, 13), most studies have focused on the impact of
DNA-PK-mediated phosphorylation on XRCC4 function (3,
14). However, phosphorylation of XRCC4 by DNA-PK cannot
account for all of its functions. For instance, DNA-PK-depen-
dent phosphorylation of XRCC4 does not appear to play a role
in mediating resistance to ionizing radiation or V(D)J recombi-
nation (3, 14). On the other hand, phosphorylation by protein
kinase CK2 mediates the interaction of XRCC4 with the fork-
head-associated (FHA) domain of PNKP and thereby stimu-
lates DNA ligation (7). An examination of the crystal structure
of a short XRCC4 phospho-peptide bound to the FHA domain
of PNKP indicated that this binding stems from electrostatic
interaction of the CK2 phosphorylated residue (Thr-233) of
XRCC4 and positively charged residues in the FHA domain of
PNKP, particularly Arg-35 (15).
Given the central role of the XRCC4 protein in NHEJ, we
initiated this study to understand the mode of interaction
between XRCC4 and PNKPwith a special emphasis on the role
of XRCC4 phosphorylation byCK2.We have identified a novel,
phosphorylation-independent interaction between XRCC4
and the catalytic domain of PNKP. Moreover, we show that
phosphorylation of XRCC4 profoundly alters its binding to
PNKP, and the two modes of binding lead to dramatically dif-
ferent responses to PNKP interaction with DNA and PNKP
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kinase activity. Our data suggest that cellular XRCC4 exists in
phosphorylated and nonphosphorylated forms and that not all
of the cellular XRCC4 is in complex with DNA ligase IV.
Intriguingly, both nonphosphorylated XRCC4 and the
XRCC4DNA ligase IV complex (X4LIV) stimulate PNKP
kinase activity, whereas CK2-phosphorylated XRCC4 (in the
absence of DNA ligase IV) inhibited PNKP activity. Together,
our data suggest that XRCC4 phosphorylation and complex-
ation have subtle effects on PNKP activity and reveal new
potential roles for XRCC4 and PNKP in NHEJ.
EXPERIMENTAL PROCEDURES
Expression and Purification of Proteins—Descriptions of
the bacterial expression and purification of wild type and
mutant human XRCC4 and PNKP are provided in the supple-
mentalmaterials. XRCC4DNA ligase IV complex (X4LIV) and
XRCC4-T233ADNA ligase IV complex (X4T233ALIV) were
expressed in baculovirus-infected insect cells and purified as
described previously (16).
In Vitro Phosphorylation of XRCC4—CK2 (17) with a GST
tag was expressed in bacteria and purified over glutathione-
Sepharose beads as described for GST-XRCC4 (see the supple-
mental materials), and the purified Sepharose bead-bound
enzyme was used in phosphorylation reactions. For production
of phosphorylated XRCC4 for biophysical characterization,
phosphorylation reactions contained 5 mg of purified XRCC4
in 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl2, and 1
mMATP. The ratio of XRCC4 to CK2 used was 5:1, and the reac-
tions were carried out at 30 °C for 2 h. At the end of the reaction,
immobilizedCK2was removed by centrifugation at 1000 g, and
the resulting supernatant was concentrated 5-fold using an
ultrafiltration unit (30-kDa cutoff) and then dialyzed into 50 mM
Tris-HCl, pH8.0, containing1mMDTTandprotease inhibitors as
above. To determine the stoichiometry of phosphorylation, a
small aliquot of the reaction was removed prior to the addition
of ATP and incubated with radioactively labeled ATP (specific
activity, 200 cpm/pmol). For phosphorylation of WT and
XRCC4-T233A for characterization of the phosphospecific
antibody to Thr-233, the reactions contained 1.5 g of purified
XRCC4 protein, and reaction volumes and the amounts of CK2
were scaled down accordingly.
To examine the interference of DNA and/or PNKP on CK2
phosphorylation of XRCC4, 50 pmol of XRCC4, PNKP, and
45-bp phosphorylated duplex DNA were preincubated in a
20-l reactionmixture containing 50mMTris-HCl, pH 7.5, 100
mM NaCl, 5 mM MgCl2 for 10 min at 30 °C. The reactions were
started by the addition of 0.2 g of GST-CK2 and 1 mM ATP
containing stabilized [-32P]ATP (specific activity, 500 cpm/
pmol) and incubated for 5 or 10 min at 30 °C. The reactions
were terminated by the addition of SDS (to 1%) and DTT (to 10
mM). The samples were heated to 100 °C for 3 min and then
analyzed by autoradiography after SDS-PAGE on a 10% poly-
acrylamide gel.
Steady-state Fluorescence Studies—Steady-state fluorescence
spectra were measured at 25 °C on a PerkinElmer Life Sciences
LS-55 spectrofluorometer with 5-nm spectral resolution for
excitation and emission as described in our earlier studies (18,
19). Unless otherwise stated, each proteinwas used at a concen-
tration of 0.1 M. The duplex DNA, supplied by Integrated
DNATechnologies (Coralville, IA), had the sequences: 5-GGC
CAG CTA GTG GTG GTG GGC GCC GGC GGT GTG GGC
ATT CGT AAT-3 and 3-CCG GTC GAT CAC CAC CAC
CCG CGG CCG CCA CAC CCG TAA GCA TTA-5. The
lower strand was used as the single-stranded substrate.
GraphPad Prism software was used for the analysis of binding
data.
Sedimentation Equilibrium—The details of our protocol are
described in the supplemental materials.
Circular Dichroism Spectroscopy—CD measurements were
performed with an Olis DSM 17CD spectropolarimeter
(Bogart, GA) as described previously (18). Protein concentra-
tions used for each determination are presented in the corre-
sponding figure legends.
PNKP Kinase Activity Assays—PNKP (1.5 g) was premixed
with 1.0 or 2.0g of XRCC4 or pXRCC4 and incubated at 37 °C
for 5 min and then added to a reaction mixture (20 l of total
volume) containing kinase buffer (80 mM succinic acid, pH 5.5,
10 mM MgCl2, and 1 mM DTT), 2 M 45-bp duplex DNA sub-
strate, and 3.3 pmol of [-32P]ATP (PerkinElmer Life Sciences)
and incubated for 20 min at 37 °C. Four l of the sample was
mixed with 2 l of 3 sequencing gel loading dye (Fisher),
boiled for 10min, and run on a 12%polyacrylamide gel contain-
ing 7 M urea at 200 V. The gel was scanned on a Typhoon 9400
variable mode imager (GEHealthcare), and the resulting bands
were quantified using ImageQuant 5.2 (GE Healthcare).
The influence of XRCC4 and pXRCC4 on the kinase activity
of PNKP under limiting enzyme conditions was carried out as
described in our previous publication with PNKP and XRCC1
(19). Briefly, two 50-l reaction mixtures containing kinase
buffer (80 mM succinic acid, pH 5.5, 10 mM MgCl2, and 1 mM
DTT), 0.4 nmol of DNA substrate, 0.4 nmol of unlabeled ATP,
3.3 pmol of [-32P]ATP, and 0.5 g of PNKP were incubated at
37 °C. Aliquots (3 l) were taken from one of the reaction mix-
tures after incubation intervals of 0, 1, 2, 5, 10, 20, or 30min. To
the other reaction mixture, 4.0 g of XRCC4 or pXRCC4 was
added after a 20-min incubation, and then 3-l aliquots were
taken after additional time intervals. The samples were mixed
with sequencing gel loading dye and analyzed as described
above. The same procedure was followed to measure the influ-
ence of the X4LIV complexes on PNKP kinase activity except
that 5 g of the complex was added 20min after the start of the
kinase reaction.
Measurement of Cellular Content of Proteins—To determine
the relative amount of each protein, purified proteins were first
quantitated by running on SDS-PAGE; then gels were stained
with Coomassie Brilliant Blue, and the bands were compared
with known amounts of BSA. HeLa cells were grown to 80%
confluence in DMEMwith 10% fetal bovine serum in a humid-
ified atmosphere of 5% CO2 at 37 °C. To generate whole cell
extracts, the cells were removed from plates by trypsinization,
washed with ice-cold PBS, and then resuspended in ice-cold
lysis NETN buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1
mM EDTA, 1% (v/v) Nonidet P-40, 1 M microcystin-LR, plus
protease inhibitors 0.2 M phenylmethylsulfonyl fluoride, 0.2
g/ml leupeptin, 0.2 g/ml aprotinin, 0.2 g/ml pepstatin).
After incubation on ice for 30 min, the extracts were sonicated
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and then clarified by centrifugation (10,000 rpm at 4 °C for 10
min). The pellet was extracted two more times with fresh lysis
buffer as above, and the final supernatants were combined. Pro-
tein concentrations were determined using the detergent com-
patible protein assay (Bio-Rad) using BSA as standard. The
amount of each protein in cell extracts was determined by
Western blot using the purified proteins as standards. Immu-
noblots were quantified using ImageQuant software. At least
three separate cell extracts were used for each experiment. Rep-
resentative immunoblots are shown.
PNKP Expression in Mammalian Cells—Vectors for expres-
sion of N-terminal HA epitope-tagged PNKP and HA-tagged
R35A-PNKP are described in the supplementalmaterials. HeLa
cells were transfected with 3 g of either vector control or
vector encoding HA-tagged PNKP (pIRESpuro3-HA-PNKP)
or HA-tagged R35A-PNKP (pIRESpuro3-HA-PNK-R35A).
Transfections were carried out using Lipofectamine 2000
(Invitrogen), according to the manufacturer’s recommended
conditions, except that 10l of Lipofectamine reagentwas used
per 1.2  106 cells.
Immunoprecipitation Reactions—For immunoprecipitation
of endogenous XRCC4 fromHeLa cells, HeLa cells were grown
and harvested, and NETN lysates were generated as described
above. Two mg of extract was precleared using protein
G-Sepharose beads (GEHealthcare), andXRCC4was immuno-
precipitated by incubation overnight at 4 °C with mouse poly-
clonal antisera to XRCC4 that had been covalently coupled to
protein G-Sepharose beads (20). The beads were washed five
times with 1 ml of lysis buffer, and immunoprecipitates were
analyzed by SDS-PAGE and probed for XRCC4 or Thr-233-
phosphorylatedXRCC4 as indicated. For immunoprecipitation
of transfected proteins, 72 h after transfection, the cells were
lysed by incubation on ice for 30 min in HEPES/Nonidet P-40
lysis buffer (40 mM HEPES, pH7.5, 1 mM EDTA, 50 mM NaCl,
0.1% (v/v) Nonidet P-40) containing 0.2 M phenylmethylsul-
fonyl fluoride, 0.2 g/ml leupeptin, 0.2 g/ml aprotinin, 0.2
g/ml pepstatin, and 1Mmicrocystin-LR, followed by sonica-
tion. Where indicated, the protein cross-linker dithiobis(suc-
cinimidyl propionate) (Thermo Scientific, Waltham, MA) was
added to 1mM final concentration, and extracts were incubated
at room temperature for 30min. The reactions were stopped by
the addition of Tris-HCl, pH 7.5, to 50 mM followed by incuba-
tion for a further 15 min at room temperature. The extracts
were then preclearedwith proteinG-Sepharose, andXRCC4 or
HA-PNKP was immunoprecipitated from 1.5 mg of extract as
described above. The beads were washed five times with 1ml of
low salt/low detergentNETNbuffer (50mMTris-HCl, pH 7.5, 5
mMEDTA, 50mMNaCl, 0.1% (v/v)Nonidet P-40, 0.2mMphen-
ylmethylsulfonyl fluoride) and analyzed by SDS-PAGE and
immunoblot as indicated.
RESULTS
Nonphosphorylated XRCC4 Co-immunoprecipitates with
PNKP in Vitro—XRCC4 is regarded as a scaffold protein that
plays a critical role inNHEJ. Previous studies have revealed that
PNKP interacts with Thr-233-phosphorylated XRCC4 via its
N-terminal FHA domain (7), suggesting that PNKP is recruited
to DSBs with the XRCC4DNA ligase IV complex. In prelimi-
nary studies, we observed that purified recombinant XRCC4
produced in Escherichia coli co-immunoprecipitated with
PNKP, suggesting that these two proteins were also capable of
interacting in a phosphorylation-independentmanner (supple-
mental Fig. S1). This observation prompted us to examine the
interaction of PNKP with both phospho- and non-phospho-
XRCC4 in more detail. XRCC4 was expressed and purified
from E. coli. To ensure that the purified protein did not contain
residual phosphorylation sites and that it was not contaminated
with DNA, where indicated, XRCC4was treated with phospha-
tase and ethidium bromide before use (see supplemental mate-
rials for details). Unphosphorylated XRCC4 is referred to as
XRCC4. Despite having amolecularmass of38,000Da, based
on its amino acid sequence, XRCC4 migrated on SDS-PAGE
with an apparentmolecular mass of55,000 Da (supplemental
Fig. S2A), consistent with published values (3, 12). The ob-
served anomalous mobility of recombinant XRCC4 in SDS-
PAGE is likely due to its low isoelectric point (21, 22). Where
indicated, XRCC4 was phosphorylated in vitro by CK2 and is
referred to as pXRCC4. The stoichiometry of phosphorylation
was1mol of phosphate/mol of XRCC4 (supplemental Fig. S2,
B and C). As expected, pXRCC4 migrated slightly more slowly
on SDS-PAGE than unphosphorylated XRCC4 (supplemental
Fig. S2B).
PNKP Interacts with Non-phospho-XRCC4 in Solution—To
further study the interaction between PNKP and pXRCC4 and
XRCC4, we used the covalent sulfhydryl-specific environment-
sensitive fluorescent probe acrylodan (AC) (23) to label PNKP.
PNKP-AC retained 90% of its kinase activity compared with
unlabeled PNKP (18). The PNKP-ACpXRCC4 interaction was
accompanied by partial quenching of AC fluorescence (excita-
tion at 380 nm) with no change in the emission maximum
(485 nm). The binding affinity,Kd, was determined by follow-
ing fluorescence quenching as a function of pXRCC4 concen-
tration. A plot of relative fluorescence intensities versus con-
centration of pXRCC4 is shown in Fig. 1A (inset). Nonlinear
regression analysis of the binding data yielded aKd value of 5 
1 nM. A similar analysis of interaction between PNKP-AC with
XRCC4 indicated that XRCC4 bound PNKP-AC, but with a
lower affinity (Kd 90  5 nM) (Fig. 1B). These data confirm that
PNKP interacts with XRCC4 in a non-phosphorylation-depen-
dent manner in vitro.
XRCC4 Interacts with the Catalytic Domain of PNKP—Pre-
vious studies have shown that pXRCC4 binds to the FHA
domain of PNKP (7). To obtain quantitative data for this inter-
action, we purified the PNKPFHA domain (residues 1–130) and
labeled the single Cys residue (Cys-46) with AC. When the
labeled protein PNKPFHA-AC was excited at 380 nm, the emis-
sion maximum occurred at 495 nm, and the addition of
pXRCC4 resulted in AC fluorescence quenching (Fig. 1C).
Titration of PNKPFHA-AC with pXRCC4 provided a Kd value of
4  1 nM, in close agreement with the value obtained with the
full-length PNKP protein. In contrast, the addition of XRCC4
had no significant effect on AC fluorescence (Fig. 1D), indicat-
ing that unphosphorylated XRCC4 does not interact with the
FHA domain of PNKP.
Wenext askedwhether the interaction of PNKPandunphos-
phorylated XRCC4 is mediated by the C-terminal catalytic
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kinase/phosphatase domain of PNKP. A C-terminal fragment
of PNKP corresponding to amino acids Lys-141 to Gly-521 was
expressed in E. coli, purified, and similarly labeled with AC
(PNKPCT-AC).When the labeled protein was excited at 380 nm,
the emission maximum centered 485 nm. The addition of
XRCC4 resulted in partial quenching of AC fluorescence and
amounted to 13% when the two proteins were mixed in a 1:1
molar ratio. Fluorescence titration (Fig. 1E) yielded aKd value of
100  10 nM, in close agreement with the Kd value obtained
with full-length PNKP. The addition of pXRCC4 induced 8%
quenching of AC fluorescence, signifying interaction between
the two proteins, but this level of
quenching was not sufficient to
allow us to determine a Kd value.
Thus, non-phospho-XRCC4 inter-
acts with the C-terminal catalytic
domain of PNKP, whereas Thr-233-
phosphorylated XRCC4 interacts
primarily with the FHA domain of
PNKP.
Interaction of PNKP with Both
Phospho- andNon-phospho-XRCC4
Produces a Conformational Change
in Both Proteins—The influence of
CK2 phosphorylation on the bio-
physical properties of XRCC4 was
examined by sedimentation equilib-
rium analysis and CD. The data
presented in supplemental Figs. S3
and S4 and Table S1 indicate that
phosphorylation of XRCC4 shifts
its dimer-tetramer equilibrium
more toward the dimeric state and
increases the proportion of random
structure found in the protein
(Table 1).
We next used CD to determine
whether the interaction of PNKP
with either pXRCC4 or XRCC4
affected the secondary structure of
either protein. Because the observed
ellipticity is an additive parameter,
one can generate the theoretical
CD spectrum for a mixture of pro-
teins by adding together the spectra
of individual proteins, and this
spectrum can be compared with
that observed experimentally to
see whether the interaction has
induced any conformational change.
The far-UVCD spectra obtained for
the [PNKPXRCC4] and [PNKP
pXRCC4] complexes (1:1 molar
ratios) are shown in Fig. 2 (A and B).
The experimentally observed ellip-
ticity values deviate from the theo-
retical values particularly in the 209-
and 218-nm wavelength regions,
demonstrating that the interaction has produced a conforma-
tional change in both complexes. For instance, for the
[PNKPXRCC4] complex, the difference between the observed
and the theoretical ellipticity values at 209 nm was 2000 deg
cm2 dmol1, whereas the experimental error in thesemeasure-
ments is only 300 deg cm2 dmol1. Comparison of the sec-
ondary structure of the complexes with the secondary struc-
tures of the individual proteins (Table 1) suggests that the
interaction between PNKP and XRCC4 resulted in an increase
in the random structure, whereas the [PNKPpXRCC4] com-
plex assumes a slightly higher -helical content at the expense
FIGURE 1. Phosphorylation of XRCC4 alters its mode of binding to PNKP. A and B, fluorescence titration of
PNKP-AC versus pXRCC4 and XRCC4. Labeled PNKP (0.3 M) was excited at 380 nm, and the relative fluores-
cence (Rel. Fluor.) intensities were monitored at 480 nm (see insets). The fraction of PNKP-AC bound versus
pXRCC4 (A) and XRCC4 (B) concentration is plotted, revealing considerably tighter binding of PNKP to pXRCC4.
C and D, effect of pXRCC4 and XRCC4 on PNKPFHA-AC fluorescence. PNKPFHA-AC was excited at 380 nm, and the
effect of pXRCC4 (C) and XRCC4 (D) on the emission fluorescence was determined. In each figure the upper (line
1) and lower (line 2) signals show the fluorescence spectrum for PNKPFHA-AC in the absence or presence of
XRCC4, respectively. E, fluorescence titration of PNKPCT-AC versus XRCC4. Labeled PNKPCT-AC was excited at 380
nm, and the relative fluorescence intensity was monitored at 480 nm (see inset). The fraction of PNKPCT-AC
bound versus XRCC4 concentration is plotted.
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of the random structure. These two protein complexes exist in
different conformational states, and this could arise from the
nature of their interactions. For instance, if XRCC4 binds to
the catalytic domain of PNKP while pXRCC4 associates with
the FHA domain, the two complexes would assume different
secondary structures.
Far-UV CD experiments also provided additional evidence
for interaction between the PNKPCT domain and XRCC4 and
pXRCC4. When the two proteins PNKPCT and XRCC4 or
PNKPCT and pXRCC4weremixed in 1:1molar ratio, the exper-
imentally observed CD spectra deviated from the calculated
theoretical CD spectra for the complexes (Fig. 2, C and D, and
Table 1). Together these data suggest that interaction of PNKP
with XRCC4 produces a conformational change.
Interaction of PNKP, XRCC4, and pXRCC4 with DNA—
Given that the natural substrate for PNKP is DNA, we asked
whether interaction of PNKP with XRCC4 affected its affinity
for DNA. Because XRCC4 has also been reported to interact
with DNA (3), we first examined the binding of each protein
individually to DNA. Quantitative data for the binding of a
blunt-ended 45-mer DNA duplex to XRCC4 and pXRCC4 was
obtained by measuring the quenching of the intrinsic Trp fluo-
rescence of the proteins at 342 nm following excitation at 295
nm as a function of DNA concentration. Binding of the 45-mer
DNA duplex to XRCC4 and pXRCC4 resulted in partial
quenching of Trp fluorescence with no change in emission
maximum, which enabled determination of binding affinities
by following fluorescence quenching as a function of 45-mer
DNA duplex concentration. A representative plot of relative
fluorescence intensity versus the concentration of duplex DNA
for XRCC4 and pXRCC4 is shown in Fig. 3 (inset). Nonlinear
regression analysis of the binding data revealed unimodal bind-
ingwithKd values of 0.28 0.03M forXRCC4 and 0.50 0.05
M for pXRCC4, respectively, indicating that phosphorylation
byCK2 did not have amajor effect on the interaction of XRCC4
with double-stranded DNA.
Because radiation-induced DSBs often contain single-
stranded termini, we also studied the binding of the unphos-
phorylated and 5-phosphorylated single-stranded 45-mer oli-
gonucleotide to XRCC4 and found that the protein bound both
oligonucleotides with similar affinities (0.70  0.05 and 0.80 
0.05 M, respectively). Hence, XRCC4 exhibits higher affinity
(2.5-fold) for double-stranded oli-
gonucleotides compared with sin-
gle-stranded oligonucleotides and is
not influenced by the phosphoryla-
tion status of theDNA. Similar anal-
ysis affordedKd values of 0.5 and 2.6
M for PNKP binding to 45-mer
duplex with 5-OH and 5-phos-
phate termini, respectively (data not
shown).
We next determined the interac-
tion of pXRCC4 with DNA in the
presence of PNKP. For these stud-
ies, PNKP was labeled with AC as
described above, and the extent
of AC fluorescence quenching in-
duced by various combinations of
pXRCC4, PNKP, and duplex DNA
(1:1 molar ratio with protein) was
determined (Table 2). (To produce
the complexes in a nearly quantita-
tive fashion, a 2-fold excess of
duplex DNA (1 M) was added to
study the effect of DNA binding on
PNKP-AC (0.5 M) in the absence
and presence of pXRCC4. The con-
centration of duplex DNA added
was higher than its Kd value for
PNKP (0.28 M).) The addition of
DNA to PNKP-AC produced 11%
FIGURE 2. Interaction of PNKP with both phospho- and non-phospho-XRCC4 produces a conformational
change in both proteins. A, far-UV CD spectrum of pXRCC4PNKP complex (0.55 mg/ml total protein) in
sample buffer (f) and the theoretical CD spectrum for an equimolar mixture of these two proteins (Œ).
B, XRCC4PNKP complex (0.5 mg/ml) (f) and the corresponding theoretical CD spectrum for an equimolar
mixture of these two proteins (Œ). C, far-UV CD spectrum of PNKPCTXRCC4 complex (0.55 mg/ml) (f) and the
theoretical CD spectrum for an equimolar mixture of these two proteins (F). D, PNKPCTpXRCC4 complex (0.6
mg/ml) (f) and the corresponding theoretical CD spectrum (F).
TABLE 1





209 nm 218 nm
% % %
XRCC4 12,400 10,600 32 30 38
pXRCC4 11,400 9,800 32 23 45
PNKP 10,100 9,250 25 55 20
XRCC4PNKPb 9,500 9,000(E)c
11,300 10,000(T) 26 35 39
pXRCC4PNKPb 9,100 82,00(E)
10,800 9,600(T) 32 34 34
aAnalysis of the CD spectra according to the method of Chen et al. (38).
bThe twoproteins in theXRCC4PNKPandpXRCC4PNKPmixturesweremixed in
a 1:1 molar ratio.
cE represents experimental values, and T represents theoretical values assuming no
protein-protein interaction.
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quenching of AC fluorescence intensity, whereas the addition
of pXRCC4 to PNKP-AC resulted in15% quenching. Because
pXRCC4 can bind duplex DNA (Kd  0.50 M), we wanted to
see whether preincubation of pXRCC4 with DNA, to allow for-
mation of a binary complex [pXRCC4DNA], would affect
binding to PNKP-AC. The addition of the [pXRCC4DNA]
complex produced 14% quenching in AC fluorescence inten-
sity, thus demonstrating that PNKP-AC can bind to this binary
complex to form a ternary complex. Likewise, the addition of
pXRCC4 to the complex of PNKP-AC bound to DNA, [PNKP-
ACDNA], induced 13% further quenching in AC fluores-
cence, thus similarly providing evidence for the formation of a
ternary complex. However, no significant additional quenching
of AC fluorescence was observed when the DNA was added to
the [PNKP-ACpXRCC4] binary complex. Hence, when
pXRCC4 was bound to PNKP, the DNA was unable to bind to
PNKP and remained free or was bound to pXRCC4 in such a
way that it did not perturb the AC fluorescence of PNKP. In
contrast, duplex DNAwas capable of binding to the complex of
PNKP with nonphosphorylated XRCC4 [PNKP-ACXRCC4]
(20% quenching), suggesting that XRCC4 and pXRCC4 affect
PNKP DNA binding in opposite ways. To determine whether
the duplex DNA bound to [PNKPpXRCC4], we mixed the
unlabeled proteins PNKP and pXRCC4 in 1:1 molar ratio and
studied the effect of adding the DNA on the intrinsic Trp fluo-
rescence of the protein complex. The addition of DNA to this
complex produced 18% quench-
ing in Trp fluorescence, thus clearly
demonstrating that DNA binds
to the [PNKPpXRCC4] complex
through interaction with pXRCC4.
Confirmation that pXRCC4
maintains binding to DNA while
bound to PNKP was shown by anal-
ysis of complex formation involving
PNKPFHA-AC, pXRCC4, and DNA.
The addition of DNA had no signif-
icant effect on AC fluorescence of
PNKPFHA-AC, which is not surpris-
ing because the DNA-binding sites
of PNKP are located in the C-termi-
nal catalytic domain. Binding of
pXRCC4 to PNKPFHA-AC induced 18% quenching in AC
fluorescence, and the addition of the binary complex
[pXRCC4DNA] produced 16% quenching in fluorescence
intensity, providing evidence for the formation of a ternary
complex involving PNKPFHA, pXRCC4, and the duplex DNA
(Table 2). In contrast, the addition of DNA to the binary com-
plex [PNKPFHA-ACpXRCC4] caused no change in AC fluores-
cence, probably because the DNA binding site on pXRCC4 is
situated far from the Thr(P)-233 residue associated with PNKP
binding.
Interaction of PNKPwith Phosphorylated XRCC4 Inhibits the
Kinase Activity of PNKP—The results of our fluorescence stud-
ies suggested that DNA was unable to bind to PNKP when
PNKP was complexed with pXRCC4.We therefore carried out
kinase activitymeasurements of PNKP in the absence and pres-
ence of pXRCC4 with the implication that the failure of PNKP
to bind to DNA would abrogate PNKP kinase activity. When
PNKP was mixed with pXRCC4 in a 1:1 molar ratio prior to
adding the 45-mer duplex DNA, the observed kinase activity of
this binary complex was 20% compared with the activity of
PNKP alone (Fig. 4A), andwhen the two proteins weremixed in
a 1:2 molar ratio, the observed activity of this complex was
further reduced to 10% of PNKP activity. In this assay, the
DNA concentration was 20-fold in excess of the PNKP, sug-
gesting that the PNKP remained tightly bound to the pXRCC4,
because it would otherwise have been able to phosphorylate the
DNA.However, when PNKPwasmixedwith XRCC4 in 1:1 and
1:2 molar ratios prior to adding the DNA, the observed kinase
activities were similar to the control levels ( 90 and 85%,
respectively). In a follow-up experiment, we preincubated
XRCC4 or pXRCC4 with DNA for 5 min at 37 °C prior to the
addition of PNKP for the kinase assay. Under these conditions,
XRCC4 had no significant effect on PNKP activity, suggesting
that the DNA had access to PNKP, whereas when the DNAwas
complexed with pXRCC4, it had very limited access to PNKP
because pXRCC4 again inhibited90%of PNKPkinase activity
(Fig. 4B). As a further control for nonspecific inhibition ofDNA
kinase activity, including the possible presence of residual unla-
beled ATP, the pXRCC4 was mixed with phage T4 polynucle-
otide kinase, but no inhibition of the T4 kinase activity was
observed (supplemental Fig. S5).
FIGURE 3. Fluorescence titration of pXRCC4 and XRCC4 with duplex (45-mer) DNA. A and B, pXRCC4 (A, 0.5
M) and XRCC4 (B, 0.5 M) in 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 5 mM MgCl2 were excited at 295 nm, and
the fluorescence intensity was monitored at 332 nm (see inset). The fraction bound, i.e. relative fluorescence
(Rel. Fluor.) intensity versus ligand concentration, is plotted.
TABLE 2
Effect of pXRCC4 and duplex DNA binding on AC fluorescence of
labeled PNKP and PNKPFHA in the absence and presence of each other
Complex Quenchinga
PNKP 	 duplex DNA 11  1
PNKPduplex DNA 	 pXRCC4 13  2
PNKP 	 pXRCC4 15  2
PNKP 	 duplex DNApXRCC4 14  2
PNKPpXRCC4 	 duplex DNA 2  1
PNKPFHA 	 duplex DNA 2  1
PNKPFHA 	 pXRCC4 18  2
PNKPFHA 	 pXRCC4duplex DNA 16  2
PNKPFHApXRCC4 	 duplex DNA 2  1
PNKPFHAduplex DNA 	 pXRCC4 16  2
PNKPpXRCC4unlabeled 	 duplex DNA 18  2
aA 2-fold excess of duplex DNA (1 M) was added to PNKP-AC (0.5 M). Labeled
PNKP and pXRCC4 were in equimolar concentration. The labeled protein,
PNKP-AC or PNKPFHA-AC, was excited at 380 nm, and the effect of pXRCC4 and
duplex DNA binding on AC fluorescence was monitored at 485 nm. The decrease
in total fluorescence intensity at 485 nm is reported as percent quenching. The
values represent the means  S.E. (n  3). The brackets indicate complexes.
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XRCC4 but Not pXRCC4 Stimulates Enzymatic Turnover of
PNKP—To further define a role for the XRCC4PNKP interac-
tion, we examined the effect of XRCC4 and pXRCC4 on the
turnover of PNKP. The kinase activity of PNKP was assayed
using a limited concentration of the enzyme with 45-mer
duplex and [-32P]ATP (Fig. 4C). The rate of product accumu-
lation decreased over the course of the assay and reached a
plateau after10min. The addition of XRCC4 at 20min (i.e. in
the plateau region) resulted in reactivation of kinase activity,
and the percentage of 32P incorporated nearly doubled. The
observed increase in kinase activity was due to PNKP because
XRCC4 itself has no kinase activity. Thus, the addition of
XRCC4 stimulated the turnover of the enzyme-product adduct.
PNKP and XRCC4 exhibit similar binding affinities for duplex
45-mer (5-OH) (Kd values of 0.5 and 0.25 M for PNKP and
XRCC4, respectively), but they had different binding affinities
for duplex 45-mer (5-phosphate), which can be considered a
product of the enzymatic reaction of PNKP. XRCC4 exhibited
higher affinity than PNKP for 5-phosphorylated DNA, withKd
values of 0.5 and 2.8 M, respectively, a difference of 5-fold.
Hence, it is conceivable that XRCC4 binds to [PNKPDNA]
binary complex and releases the product (bound phosphory-
lated DNA) from PNKP by virtue of its higher affinity than
PNKP, thus freeing the enzyme to continue its enzymatic activ-
ity. In marked contrast, when pXRCC4 was added to the enzy-
matic reaction mixture at 20 min in the plateau region, there
was no significant reactivation of the kinase activity of PNKP.
Thus, XRCC4 but not pXRCC4 stimulates PNKP enzymatic
turnover.
The XRCC4DNA Ligase IV Complex (X4LIV) Stimulates
PNKP Enzyme Turnover—XRCC4 interacts with the tandem
BRCT domains of DNA ligase IV in a stable, phosphorylation-
independent manner (13, 24, 25). Indeed, because XRCC4 sta-
bilizes DNA ligase IV, it has been suggested that the cellular
pool of DNA ligase IV is complexed with XRCC4.We therefore
asked whether the X4LIV complex affected PNKP activity in a
similar manner to free XRCC4. For these experiments, the
X4LIV was expressed in baculovirus-infected insect cells. The
protein content of the X4LIV preparations is shown in supple-
mental Fig. S6. Significantly, X4LIV complex purified from
baculovirus infected insect cells did not inhibit PNKP kinase
activity (Fig. 5A); indeed, it had a slightly stimulatory effect. It
was therefore important to determine whether the X4LIV
complex was indeed phosphorylated on Thr-233. To do this, a
phosphospecific antibody was generated and shown to be spe-
cific for Thr-233 in vitro (supplemental Fig. S7). Comparison
with in vitro phosphorylated XRCC4 showed that baculovirus
prepared X4LIV was indeed phosphorylated at Thr-233 (sup-
plemental Fig. S8). We therefore generated a X4LIV complex
inwhichThr-233 had beenmutated to alanine (X4T233ALIV).
Surprisingly, X4T233ALIV stimulated PNKP to a similar
extent as phospho-X4LIV (Fig. 5A). Thus, in contrast to bacte-
rially expressed, CK2-phosphorylated pXRCC4, Thr-233-
phosphorylated XRCC4 in the context of the X4LIV complex
does not inhibit PNKP activity. We also examined the effect of
baculovirus expressedX4LIV complex on PNKP turnover. Sig-
nificantly, both endogenously phosphorylated X4LIV complex
and X4T233ALIV complex stimulated PNKP turnover to a
similar extent (Fig. 5B).
XRCC4 Phosphorylation and Complexes in Human Cells—In
summary, our data so far using bacterially expressed XRCC4
alone show that non-phospho-XRCC4 interacts with the cata-
lytic domain of PNKP, and this interaction stimulates PNKP
kinase activity, whereas interaction with pXRCC4 impedes
PNKP phosphorylation of DNA. In contrast, baculovirus
expressed X4LIV complex stimulates PNKP enzymatic turn-
FIGURE 4. pXRCC4 inhibits the DNA kinase activity of PNKP. A, XRCC4 and
pXRCC4 were added to PNKP and incubated for 5 min at 37 °C prior to starting
the assays. The molar ratios of PNKP to XRCC4 or pXRCC4 used were 1:1 and
1:2, respectively. The kinase activity is expressed as relative 32P incorporated,
taking the value for reaction with PNKP alone as 100%. B, XRCC4 and pXRCC4
were added to 45-mer duplex DNA and incubated for 5 min at 37 °C prior to
the measurement of kinase activity. C, XRCC4 but not pXRCC4 influences the
kinetics of phosphorylated product accumulation. The concentration of
45-mer duplex DNA was 4 M, and the PNKP concentration was 0.35 M. At 20
min of incubation, 0.70 M of XRCC4 or pXRCC4 were added. The assays were
carried out four times as described under “Experimental Procedures,” and a
representative plot is shown.
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over activity regardless of Thr-233 phosphorylation status, and
X4LIV containing nonphosphorylatedXRCC4does not inhibit
PNKP kinase activity. These new findings prompted us to
investigate XRCC4 complex formation and phosphorylation in
mammalian cells. We first estimated the relative levels of
XRCC4, DNA ligase IV, and PNKP in HeLa cells. Whole cell
extracts were generated, and the signals in immunoblots were
compared with those of calibrated amounts of the purified pro-
teins (supplemental Figs. S9 and S10 and Table 3). Our mea-
surement of the cellular levels of XRCC4 indicated the presence
of 2 XRCC4 molecules to every PNKP molecule, as well as
6-fold excess of XRCC4 relative to DNA ligase IV, suggesting
that at the cellular level, a population of XRCC4 exists that is
not complexed with DNA ligase IV and would therefore be
available to interact with other NHEJ proteins, including
PNKP.
We also examined the phosphorylation status of XRCC4 in
cells. XRCC4 migrated as a doublet on SDS-PAGE that col-
lapsed to a single band upon incubation with  phosphatase,
clearly indicating that the upper band of the XRCC4 doublet is
due to phosphorylation (supplemental Fig. S10B). The ratio of
the upper phosphorylated band to the lower band was 50:50,
suggesting that at least 50% of the cellular XRCC4 is phosphor-
ylated. To determine the extent of Thr-233 phosphorylation of
cellular XRCC4, XRCC4 was immunoprecipitated from HeLa
cells, and immunoblots were probed for Thr-233 phosphoryla-
tion. Thr-233-phosphorylated XRCC4 was found predomi-
nantly in the lower band of theXRCC4 doublet (Fig. 6). Thus, at
most approximately half of the cellular XRCC4 is phosphory-
lated on Thr-233. Neither the kinases responsible for phosphor-
ylation of the upper band of the XRCC4 doublet nor the effects
of these phosphorylation events are known; however, these
results do suggest that a significant fraction of endogenous
XRCC4 is not phosphorylated on Thr-233 and therefore could
be available for interaction with PNKP in a non-FHA-mediated
manner.
To determine whether PNKP interacted with XRCC4 in a
non-FHA-dependent manner in cells, HeLa cells were trans-
fected with either HA-tagged wild type PNKP or HA-tagged
PNKP containing an alanine mutation at Arg-35 (HA-PNKP-
R35A), a mutation that has been shown to ablate FHA domain
function (7). The taggedWT andmutant PNKPwere immuno-
precipitated, and precipitates were probed for XRCC4. Because
the interaction between PNKP and non-phospho-XRCC4 is
relatively weak with a binding constantKd of 90 nM (this study),
extracts were treated with the thiol-cleavable cross-linker,
dithiobis(succinimidyl propionate), prior to immunoprecipita-
tion to stabilize protein-protein interactions (26). As shown in
Fig. 7A, HA-PNKP-R35A immunoprecipitated endogenous
XRCC4 in dithiobis(succinimidyl propionate)-treated extracts,
consistent with an FHA-independent interaction between
XRCC4 and PNKP. This interaction was specific for XRCC4
and FHA-mutated PNKP because no interaction was observed
with the unrelated protein Mre11 (Fig. 7). In reciprocal reac-
tions, we show that antibodies to XRCC4 immunoprecipitated
FIGURE 5. Influence of XRCC4DNA ligase IV complex on PNKP kinase
activity. A, pXRCC4, X4LIV, and X4T233ALIV were added to PNKP and incu-
bated for 5 min at 37 °C prior to the measurement of kinase activity. The molar
ratios of PNKP and pXRCC4 or complex used were 1:2. B, stimulation of PNKP
kinase activity by XRCC4DNA ligase IV complexes. We followed the condi-
tions described under “Experimental Procedures.”
FIGURE 6. Approximately 50% of endogenous XRCC4 is phosphorylated
on Thr-233 in vivo. XRCC4 was immunoprecipitated (IP) from HeLa cells, and
immunoblots were probed with a phosphospecific antibody to Thr-233 or a
polyclonal antibody to XRCC4 as indicated. Lane 1, contained a mock immu-
noprecipitation with preimmune serum (pre). Lanes 2 and 3, immunoprecipi-
tated XRCC4. After immunoprecipitation, the sample in lane 3 was incubated
with  phosphatase prior to SDS-PAGE. Lane 4, 40 ng of mock-phosphorylated
XRCC4. Lane 5, 20 ng of CK2-phosphorylated XRCC4. Lane 6, 40 ng of CK2-
phosphorylated XRCC4. The major Thr(P)-233 cross-reacting band (upper
panel, lane 2) lined up with the lower band of the XRCC4 doublet (lower panel,
lane 2).
TABLE 3
Estimation of relative amounts of XRCC4, DNA ligase IV, and PNKP in
50 g of human (HeLa) cell extract
Protein Amount Molar quantitya
ng pmol
XRCC4 4.4  1.4 0.117
DNA ligase IV 1.7  0.5 0.017
PNKP 2.9  0.1 0.052
a Molar quantities of XRCC4, DNA ligase IV, and PNKP were determined using
molecular masses of 38,000, 104,000, and 57,100, respectively.
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both WT PNKP and R35A-PNKP (Fig. 7B), again consistent
with an FHA-independent interaction between XRCC4 and
PNKP. Together, our cellular data show that (i) not all of the
endogenous XRCC4 in human cells is phosphorylated on Thr-
233; (ii) XRCC4 is present in excess of DNA ligase IV, suggest-
ing that not all of the cellular XRCC4 is in complex with DNA
ligase IV; and (iii) XRCC4 can interact with PNKP in an FHA-
independent manner in vivo.
Phosphorylation of XRCC4 by CK2 in the Presence of DNA
andPNKP—LikeKoch et al. (7), we observed constitutive phos-
phorylation of XRCC4 at Thr-233 in unirradiated cells (Fig. 6
and supplemental Fig. S10), implying that Thr-233 phosphory-
lation does not require the presence of DNA DSBs. Moreover,
phosphorylation of XRCC4 on Thr-233 did not increase after
IR (data not shown), indicating that it is not DNA damage-
inducible. However, these observations do not rule out the pos-
sibility that such phosphorylation may occur when XRCC4 is
bound atDSBs.We therefore investigatedwhether humanCK2
was capable of phosphorylating XRCC4 while bound to DNA
and/or PNKP (Fig. 8). Preincubation of XRCC4with PNKP had
no significant effect on the extent of phosphorylation ofXRCC4
compared with the phosphorylation of XRCC4 alone, but the
presence of DNA dramatically inhibited CK2 activity, as has
previously been shown for Xenopus laevis CK2 (27), and this
was not ameliorated by the additional presence of PNKP.
DISCUSSION
PNKP is required to process unligatable strand break termini
generated directly bymany genotoxic agents (28) or as interme-
diates in repair pathways (29) and thus often plays a major role
in DNA single- and double-strand break repair. The clinical
importance of its activity has recently been emphasized by the
discovery of an autosomal recessive disorder resulting from
mutations in PNKP, which gives rise to microcephaly and sei-
zures (30). Key partners of PNKP in single- and double-strand
break repair are the scaffold proteins, XRCC1 and XRCC4,
respectively. Although it is generally considered that interac-
tion between PNKP and these proteins is mediated by the bind-
ing of CK2-phosphorylated scaffold protein to the FHAdomain
of PNKP (7, 31), we have recently shown that XRCC1 can inter-
act with the catalytic domain of PNKP and stimulate PNKP
activity (19, 32). These observations prompted us to examine
the interactions between unphosphorylated XRCC4, CK2-
phosphorylated XRCC4, and PNKP to improve our under-
standing of the mechanism by which these proteins function
during NHEJ.
Biophysical Interactions of XRCC4 and pXRCC4 with PNKP—
Our in vitro data clearly established a phosphorylation-inde-
pendent interaction of bacterially expressed XRCC4 with
PNKP and further indicated that XRCC4 and CK2-phosphory-
lated XRCC4 (pXRCC4) bind to PNKP at different sites.
PNKP-AC exhibited strong affinity for pXRCC4with aKd value
of 5.0  1.0 nM, which was almost identical to the Kd value of
4.0  1.0 nM obtained for the interaction of PNKPFHA-AC with
FIGURE 7. PNKP interacts with XRCC4 in an FHA-independent manner.
HeLa cells were either untransfected (–, lane 1), transfected with vector alone
(v, lanes 2 and 5), HA-tagged WT PNK (wt, lanes 3 and 6), or HA-tagged R35A-
PNK (R, lanes 4 and 7). Seventy-two hours later, the cells were lysed, and
extracts were incubated in the presence of dithiobis(succinimidyl propio-
nate), a thiol cleavable protein cross-linker as described under “Experimental
Procedures.” A, HA-tagged PNKP was immunoprecipitated (IP), and immuno-
precipitates were analyzed by SDS-PAGE and Western blot using antibodies
to HA (PNKP), XRCC4, DNA ligase IV, or Mre11 (negative control) as indicated.
Lanes 2– 4 contained 50 g of extract preimmunoprecipitation (input). Lane 1
contained 50 g of whole cell extracts from untransfected HeLa cells. B, as in
A, except endogenous XRCC4 was immunoprecipitated. The immunoblots
were probed as indicated.
FIGURE 8. Preincubation of XRCC4 with DNA inhibits phosphorylation of
XRCC4 by CK2. Purified XRCC4 (50 pmol) was incubated with 0. 2 g of CK2
and [-32P]ATP alone (lanes 1 and 3) or in the presence of 50 pmol 5-phos-
phorylated duplex DNA (lanes 2 and 4), in the presence of 50 pmol PNKP (lanes
5 and 7), or in the presence of both DNA and PNKP (lanes 6 and 8) as described
under “Experimental Procedures.” The control lanes (lanes 9 and 10) show CK2
incubated alone with [-32P]ATP or with additional PNKP. The reactions were
analyzed on SDS-PAGE, and the gel was stained with Coomassie Blue (A) fol-
lowed by autoradiography (B).
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pXRCC4, indicating that this tight interaction is with the FHA
domain of PNKP and is mediated by the phosphorylation of
Thr-233 on XRCC4. In contrast, unphosphorylated XRCC4
boundPNKP-ACwith a lower affinity (Kd 90 5nM) andhad
no significant effect on AC fluorescence when added to PNK-
PFHA-AC, implying that XRCC4 binding is associated with the
C-terminal catalytic kinase/phosphatase domain and not the
FHA domain of PNKP. This was confirmed by the observation
that XRCC4 quenched the AC fluorescence when mixed in 1:1
molar ratio with PNKPCT-AC, yielding a Kd value of 100  10
nM, in close agreement with the Kd value obtained with full-
length PNKP. Far-UV CD measurements also demonstrated
interaction between XRCC4 and PNKPCT, because the experi-
mentally observed CD spectrum for the XRCC4PNKPCT com-
plex deviated from the theoretical CD spectrum.
The bimodal physical interaction of XRCC4 with PNKP
observed here is similar to that of XRCC1; however, the effects
of XRCC1 and XRCC4 on PNKP activity are dramatically dif-
ferent. In the case of XRCC1, both the CK2-phosphorylated
and the nonphosphorylated protein stimulate PNKP kinase
activity by enhancing PNKP dissociation from the phosphory-
lated substrate (19, 31–33). Furthermore, phosphorylation of
XRCC1 elevates the stimulation of PNKP by XRCC1 (31, 32).
This contrasts significantly with the pattern of activity dis-
played by XRCC4. Under circumstances designed to test for
enzyme turnover, unphosphorylated XRCC4 was shown to
stimulate PNKP kinase activity, whereas the CK2-phosphory-
lated protein not only failed to stimulate PNKP but actually
inhibited PNKP kinase despite the formation of a ternary com-
plex with PNKP and DNA. The interactions monitored by fluo-
rescence clearly indicated that despite the presence of a large
excess of DNA, pXRCC4 prevented the DNA from binding to
PNKP within this complex. The PNKP-pXRCC4 interaction
requires a region of pXRCC4 encompassing amino acid resi-
dues 213–250,whereas theDNA-binding region inXRCC4 is at
the base of the head domain (spanning residues 1–200, with a
requirement for residues 1–28 as well as residues 168–200) (3).
Thus, the binding of DNA to pXRCC4 would be expected to
maintain the DNA at a sufficient distance from PNKP-AC to
prevent its interaction with the acrylodan dye. Both PNKP and
pXRCC4 are capable of binding the DNA duplex with similar
affinities (Kd  0.5 M); hence themost likely explanation for
the failure of PNKP to bind DNA in the tripartite complex is
that binding to pXRCC4 physically occludes the DNA-binding
sites (both kinase and phosphatase) of PNKP. Alternatively,
binding of pXRCC4 to the FHA domain might cause a signifi-
cant conformational change in PNKP that distorts the DNA-
binding sites.We consider this possibility less likely because the
linker region (residues 111–144) between the FHA domain and
the catalytic domain is extremely flexible (15).
The effect of CK2-phosphorylated XRCC4 on PNKP activity
was in sharp contrast to that of baculovirus expressed X4LIV
complex. Although XRCC4 in the context of the X4LIV com-
plex was phosphorylated on Thr-233, X4LIV did not inhibit
PNKP kinase activity. Thus, the inhibition of PNKP activity by
pXRCC4 is suppressed when in the X4LIV complex. We have
yet to identify the reason for the altered behavior of pXRCC4 in
this context. One possibility is that binding of the ligase to
pXRCC4 alters its interaction with DNA. In this regard, it is
interesting to note that Drouet et al. (34) reported that the
recruitment of XRCC4 to strand break termini is severely cur-
tailed in the absence of DNA ligase IV.However, like bacterially
expressed XRCC4, X4LIV did stimulate PNKP enzyme turn-
over, and this was independent of Thr-233 phosphorylation
status (Fig. 5).
XRCC4PNKP Interactions within NHEJ—To date XRCC4
has been considered a scaffold protein that is recruited to and
maintained at the site of damage by interaction with the Ku
heterodimer (35, 36). DNA-PKcs subsequently stabilizes the
recruited XRCC4 at DSBs. After this initial recruitment phase,
the recruited proteins are thought to form large complexes by
interacting with freely migrating unbound proteins, such as
PNKP. Because of the tight binding ofXRCC4 toDNA ligase IV,
it has been argued that DNA ligase IV would be co-recruited
with XRCC4 (36, 37). The discovery that phosphorylation of
XRCC4 by CK2 gives rise to a high affinity interaction with the
FHAdomain of PNKP, and this interaction enhances ligation of
radiation-induced DNA DSBs, further supported the scaffold/
recruitment function of XRCC4 (7). However, the data pre-
sented here suggest that the involvement of XRCC4 in NHEJ is
more complicated than previously thought. Specifically, we
show that 50% of XRCC4 in HeLa cells is phosphorylated on
Thr-233. In addition, XRCC4 is present in molar excess over
DNA ligase IV and PNKP. Together, these data suggest that not
all of the cellular XRCC4 is in complex with DNA ligase IV, and
because not all of the cellular XRCC4 is phosphorylated on
Thr-233, approximately half of the XRCC4 would not be avail-
able for the high affinity FHA-mediated interactionwith PNKP.
We hypothesize that cells may contain multiple populations of
XRCC4, some phosphorylated on Thr-233 and some not, some
in complex with DNA ligase IV and some without, and that
these proteins and protein complexes have subtly different
effects on PNKP activity that may influence NHEJ and other
repair pathways (summarized in Fig. 9). Our data suggest that
one function for XRCC4 is the displacement of PNKP from
processed strand break termini. This can be accomplished by
nonphosphorylated XRCC4 alone or by phosphorylated or
nonphosphorylated X4LIV complex. A second likely role for
FIGURE 9. Summary of effects of phospho-XRCC4 and non-phospho-
XRCC4 on PNKP activity.
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XRCC4 is the recruitment of DNA ligase IV to seal the breaks
after PNKP processing of the termini. Such recruitment would
presumably be enhanced by the tight binding between pXRCC4
and the FHA domain of PNKP and would explain the observa-
tion for phospho-dependent stimulation ofDNAend joining by
PNKP (7). Further experiments will be required to establish
whether XRCC4 is essential for recruitment of PNKP to DSB
termini in the cell.
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